表观遗传学抗肿瘤药物的临床研究进展

Clinical research progress of epigenetic anti-cancer drug

作为遗传学的分支学科之一,表观遗传学可以通过DNA甲基化、染色质重塑、组蛋白修饰、非编码RNA调控、基因组印记、基因沉默及RNA编辑等调控机制影响肿瘤的发生和进展,以此为靶点的新药研发成为抗肿瘤药物的研发热点之一。现通过对表观遗传学抗肿瘤药物在不同治疗领域的临床研究进展、联合治疗及其在耐药机制方面的临床研究进展作综述,旨在为后续研究以及该类药物在临床上的使用提供依据。

As one of the branches of genetics,epigenetics can affect the occurrence and progression of tumors through DNA methylation,chromatin remodeling,histone modification,non-coding RNA regulation,genomic imprinting,gene silencing,RNA editing and other mechanisms.The research and development of new drugs targeting epigenetics has become one of the hotspots of anti-cancer drugs.This article reviews the clinical research progress of epigenetic anti-cancer drugs in different therapeutic fields,combination therapy and researches in drug resistance,to provide an evidence for the follow-up research and clinical usage of these drugs.